EssilorLuxottica (OTCMKTS:ESLOY – Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.
Profitability
This table compares EssilorLuxottica and Guided Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| EssilorLuxottica | N/A | N/A | N/A |
| Guided Therapeutics | N/A | N/A | -274.24% |
Valuation and Earnings
This table compares EssilorLuxottica and Guided Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| EssilorLuxottica | $32.23 billion | 2.82 | $2.62 billion | N/A | N/A |
| Guided Therapeutics | $770,000.00 | 28.59 | -$3.20 million | ($0.04) | -5.70 |
EssilorLuxottica has higher revenue and earnings than Guided Therapeutics.
Analyst Recommendations
This is a summary of recent recommendations and price targets for EssilorLuxottica and Guided Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| EssilorLuxottica | 0 | 2 | 5 | 2 | 3.00 |
| Guided Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Volatility & Risk
EssilorLuxottica has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
Insider and Institutional Ownership
0.0% of EssilorLuxottica shares are owned by institutional investors. Comparatively, 9.7% of Guided Therapeutics shares are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
EssilorLuxottica beats Guided Therapeutics on 7 of the 10 factors compared between the two stocks.
About EssilorLuxottica
EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, and Optifog brands. It also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the Essilor Instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. In addition, the company provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native, Luxottica, Sferoflex, Bolon, Molsion, DbyD, and Unofficial and Seen, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
About Guided Therapeutics
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Receive News & Ratings for EssilorLuxottica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EssilorLuxottica and related companies with MarketBeat.com's FREE daily email newsletter.
